Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|May 26, 2010

Diagnostic Imaging

  • Diagnostic Imaging Vol 32 No 5
  • Volume 32
  • Issue 5

Breast-specific gamma scans monitor chemo

Breast-specific gamma imaging is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy, according to a study presented at the American Society of Breast Surgeons' annual meeting in Las Vegas.

Breast-specific gamma imaging is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy, according to a study presented at the American Society of Breast Surgeons' annual meeting in Las Vegas.

In their 12-subject study, George Washington University Hospital researchers found gamma imaging accurately establishes tumor size within 5 mm after neoadjuvant chemotherapy. The pathologic size ranged from 2.6 cm to 2 mm postchemotherapy. In addition, the correlation coefficients are superior to those of other modalities, including physical exam, mammography, ultrasound, MRI, and FDG-PET, according to the authors.

The researchers compared gamma camera breast tumor images postchemotherapy with pathologic size at excision. They found the gamma imaging accurately reflected tumor size in all 12 patients.

Related to this article

See the Real-World Impact of AI in Radiology
AI has to do more than show potential. It has to deliver measurable results.The Rad AI Outcomes and Market Impact Compendium brings together real-world clinical, operational and financial evidence from health systems, academic medical centers and radiology practices using Rad AI Reporting, Impressions and Continuity.Explore results including 60+ minutes saved per radiologist shift, a 47% reduction in report error rates, 70%+ patient follow-up adherence and >7x ROI — plus, case studies showing how organizations are translating AI into greater capacity, quality and financial performance.See what AI built specifically for radiology can deliver in practice.